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Abstract
Hepatitis C virus (HCV) is the leading cause of chronic hepatitis worldwide and its subtypes/genotypes are clinically
important for clinical management and vaccine development. The present study describes frequency distribution
of different HCV genotypes and their treatment status in HCV RNA positive patients from district Swat. A total of
185 HCV infected sera were analyzed by molecular genotyping assay. The most prevalent genotype was 3a (34.1%),
followed by 2a (8.1%), 3b (7%) and 1a (5.4%). The samples found untypable by the present method of genotypes
was 37.8% while, patients with mixed genotype infections were 7.6%. More than 80% of untypable cases were
from those HCV patients who had received interferon plus ribavirin standard therapy in the past and either were
non-responders and were relapsed thereafter or were under treatment. In conclusion, genotype 3a is the most
prevalent HCV genotype in the region. A high prevalence rate of untypable genotypes is present in treated
patients that need further investigation for the successful genotyping by developing new assays or using viral
sequencing method.
Background
Hepatitis C virus (HCV) is a positive single strand RNA
virus of Flaviviridae family [1,2] that is approximately
9.6 Kb in length having a 5’ non-coding region (5’NCR),
a long open reading frame (ORF) encoding a polypro-
tein precursor of 3,000 amino acids and 3’NCR. Func-
tions of 5’NCR as an internal ribosomal entry site
(IRES) is important for cap-independent translation of
the viral RNA [3]. The virus infect hepatocytes and B
lymphocytes of human cells [4,5], and produce 10 tril-
lion virus particles per day, even in the late phase of
infection [1]. Viral infection is the major cause of liver
cirrhosis in approximately 20% of patients that after
10 years lead to hepatocellular carcinoma (HCC) in a
subset of incidence of 3%per year [6]. The infection is
also associated with cryoglobulinaemia [7] non-Hodg-
kin’s lymphoma [8] and glomerulonephritis [9]. There
are 200 million people of the world population are
infected with HCV [10] of which the seroprevalence rate
is about 1% in North America, Mediterranean and in
Asian countries it is about 3-4%, while in central Africa
and Egypt it is 10-20% [11,12].
Globally six major Hepatitis C virus (HCV) genotypes
and multiple subtypes have been identified and are gen-
erally studied for epidemiology, vaccine development
and clinical management of the infection [13]. Inter-
feron in combination with ribavirin is the only available
approved treatment for chronic hepatitis C [14]. In
Western patients the initial responses have been
reported to be between 40-70% but sustained response
was noted in only 10-25% after treatment [15]. Evidence
shows that HCV genotype 2 and 3 infected patients are
more likely to have a sustained virological response to
anti-viral treatment than genotype-1 infected patients
[16]. Combine treatment with interferon and ribavirin
have 65% and 30% sustained virological response to
HCV genotype 2, 3 and 1 respectively [17,18].
The worldwide distribution and relative prevalence of
these three HCV genotypes varies from one geographic
region to another. In the United State of America and
Europe the most common subtypes are 1a and 1b
[19-21], While subtype 1b is most commonly found in
Japan [22]. HCV Subtype 2a and 2b are mostly found in
North America, Europe, and Japan while 2c is found
only in northern Italy [16,20-22]. In North Africa and
the Middle East the most common genotype is 4 while
genotype 5 and 6 are found in South Africa and Hong
Kong, respectively [23,24]. Genotypes 7, 8, and 9 have
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and 11 are commonly found in Indonesian patients [26].
It has been proposed that genotypes 7 through 11
should be consider as variants of the same group and
classified as a single genotype, type 6 [27,28].
On the distribution of hepatitis C virus genotypes,
only a few numbers of studies are available from Punjab
and Sindh provinces of Pakistan [29-31]. The frequency
distribution of various HCV genotypes in Khyber Pakh-
toonkhaw (KPK) are recently reported in one study [13]
in which HCV genotypes 1a, 1b, 3a and 3b are com-
monly found in various parts of KPK among these geno-
types 3a is frequently available [13]. Study on the
molecular genotyping of HCV prevalent in KPK is lim-
ited. Therefore, this study was conducted to find out the
molecular epidemiology of various HCV genotypes and
subtypes present in Swat district of KPK.
Methods
Subjects
A total of 185 patients infected with Hepatitis C virus
were selected for HCV Genotyping. Informed consent
was taken from each infected patient, containing age,
sex, demographic characteristic, apparent mode of dis-
ease transmission, area/district, and estimated time of
infection along with complete address and contact num-
bers of the patients. Blood samples were collected from
patients by visiting hospitals in different area of swat.
Qualitative PCRs for HCV RNA
Reverse transcriptase (RT) PCR described by idress et al
[30] was done for the detection of HCV RNA. RNA was
isolated from 100 μlp a t i e n t ’ss e r au s i n gQ u i g e nR N A
extraction kit according to the kit protocol. Nested PCR
were performed using Taq DNA polymerase enzyme
(Fermentas Technologies USA) in a volume of 20 μl
reaction mix. The nested PCR products were visualized
on 2% agarose gel.
Genotyping of HCV
Type-specific HCV genotyping procedure as described
previously in detail [31] was used. About 10 μlo fH C V
RNA was reverse transcribed to cDNA using 100 U of
M-MLV RTEs at temperature of 37°C for 50 minutes.
Two μl synthesized cDNA was used for PCR amplifica-
tion of 470-bp region from HCV 5’NCR along with core
region by first round PCR amplification. The amplified
first round PCR product were subjected to two second
rounds nested PCR amplifications. One with mix-I pri-
mers set and the second with mix-II primers set in a
reaction volume of 10 μl mix-I had specific genotype
primers set for 1a, 1b, 1c, 3a, 3c and 4 genotypes and
mix-II contain specific genotype primers set for 2a, 2c,
3b, 5a, and 6a genotypes.
After second round of PCR, the products were
separated by 2% agarose gel and ethidium bromide was
used for staining to visualize the gel under UV transillu-
minator. A DNA ladder of 100-bp (Invitrogen, Corp.,
California, USA) was run in each gel as DNA size marker
and the HCV genotype for each sample was confirmed
by HCV genotype-specific PCR band. Gel documentation
system (Geldoc System, Eppendorf Inc, Germany) was
used for gel photograph. The sensitivity of the assay is
about 250 IU per ml sample and specificity is 97%.
Statistical analysis
Data was analyzed and summarize by using statistic
software SPSS version 16.0 for windows. ANOVA and
t-test was applied to assess the statistical significance of
the data. The data was obtainable as mean values or
number of patients. P-value less than 0.05 was consid-
ered as significant.
Results
Total of 185 HCV positive samples from district Swat
were selected for HCV genotype analysis. Among them
105 (56.8%) were males and 80 (43.2%) were females
with 171 (92.4%) married and only 14 (7.6%) unmarried
patients. Mean age of the patients was 34.72 years. Most
of the patients had no previous history of drug addic-
tion, only 17 (9.2%) and 25 (13.5%) of the patients were
smokers and snuff users respectively while, no patient
was observed with injection drug use.
Table 1 shows age wise distribution of different geno-
types prevalent in District Swat. Total no of patients
successfully genotyped were 115 (62.16%). Total number
of HCV 3a genotype samples were 63 (34.1%), 2a (8.1%),
3b (7%) and 1a (5.4%). Mixed infections of two different
genotypes were observed in 14 (7.6%) while 70 (37.8%)
of the patients were untypable by the mentioned
method. This shows that most prevalent genotype is 3a
followed by 2a, 3b and 1a. High HCV infection rate of
42.7% was observed in the age group of 20 to 30 years
while only 0.5% of the patients were of the age above
60 years. The HCV infection was found more prevalent
Table 1 Age wise distribution of the patients genotyped
Age in years Genotype
3a 2a 1a 3b Untypable Mixed Total
10-20 1 1 0 0 4 0 6 (3.24%)
20-30 27 5 5 8 26 8 79 (42.7%)
30-40 18 3 2 2 20 3 45 (24.32%)
40-50 13 4 2 3 17 2 41 (22.16%)
50-60 3 2 0 0 1 1 7 (3.78%)
>60 1 0 1 0 2 0 4 (2.16%)
Total 63 15 10 13 70 14 185
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persons.
Table 2shows successfully genotyped and non-geno-
typed samples based on anti-viral treatment status of
the patients. Of the total 70 untypable cases, 58 (47.9%)
were from those patients who had received or were
receiving interferon plus ribavirin standard therapy in
the past and either were non-responders or were
relapsed thereafter and only 1 (9.1%) was from untreated
group. Those patients who were unaware about their
treatment status in the past, 11 out of 53 (20.8%) were
found with untypable genotypes.
Different mode of contamination of various HCV
g e n o t y p e si sc l e a rf r o mt a b l e3 .I n2 6 . 4 8 %o ft h eH C V
infected population the mode of contamination was sur-
geries, in 12.4% was blood transfusion, 10.8% (pregnant
females) got infection during deliveries and 10.3% had
visited foreign countries especially Afghanistan in past
and probably got infected over there. The mode of con-
tamination was unknown in 40.0% of the infected
individuals.
Results of the multivariate ANOVA showed that the
genotype prevalence is independent of age of the patient
(p = 0.879), gender (p = 0.214) and marital status (p =
0.291) at 95% confidence interval (a = 0.05). Similarly,
treatment status of the patients were also shown to be
independent of age, gender and marital status (p > 0.05)
at 95% CI. Analysis of paired sample t-test showed that
all the six different genotypes are independent of age of
the patients (p > 0.05) at CI of 95%.
Discussion
Swat is a district with a population of 12’57’602 (accord-
ing to 1998 censuses) located in the Khyber Pakhtoon-
khaw (KPK) province of Pakistan [32]. Hepatitis C virus
seropositivity in Swati population was reported to be
13.8% while HCV RNA positivity was 4.7% [33]. In this
study, 185 HCV RNA positive samples were analyzed
for genotyping. The most prevalent genotype was 3a
(34.1%), followed by 2a (8.1%), 3b (7%), 1a (5.4%) while,
mixed genotype infection were 7.6%. The rate of untyp-
able genotype was 37.8% in the current study. Recently
Ahmad et al. [33] investigated the prevalence of differ-
ent genotypes in district Swat and found 49.5% preva-
lence of 3a genotype, 3b (3.2%), mixed genotypes
infection (8.7%) and untypable (3.6%) [13]. Ali et al. [33]
genotyped 415 HCV positive patients from KPK
province and reported 3a (57.83%), 3b (6.2%), 1a (072%),
mixed genotypes (6.73%) and untypable (27.95%). The
authors of both the studies described above were unable
to establish the status of treatment in their enrolled
patients. In another study from Lahore (a populated city
in Pakistan), Ahmad et al. [34] reported 3a (55.9%), 3b
(3.2%), 1a (23.6%), mixed genotypes (1.2%) and untyp-
able (2.5%). A more detailed study from Pakistan
showed the prevalence of 3a (62%), 3b (9%), 1a (3%), 2a
(2.144%), mixed (4.718%) and untypable (17.16%) [34].
The present study shows high prevalence of 2a of 8.1%
genotype in Swati population as compared to that
reported from the rest of the country. Genotypes 2a is
common in Europe, North America and Japan [35]
which suggest that this genotype may be introduced due
to frequent traveling of the local population to these
countries.
The high percentage of untypable HCV genotype seen
in the current study is due to the status of patients sam-
ples used for HCV genotyping as 82.9% of our untypable
cases were from those HCV patients who had received
interferon plus ribavirin standard therapy in the past
and either they were non-responders or initially
responded to therapy (end of treatment response) but
later on were relapsed. It is convincing that this high
number of samples with untypable genotypes is due to
mutations and emergence of new quasispecies that
emerged during therapy due to drugs pressure.
HCV mutates very rapidly during its replication cycle
that permits for the emergence of drug resistance muta-
tions that is very common. Rapid emergence of new
Table 2 Successfully genotyped and non-genotyped samples based on anti-viral treatment status
Treatment Status Number of patients samples Successfully genotyped (%) Found untypable (%)
Previously received interferon plus ribavirin therapy 121 63 (52.1) 58 (47.9)
Never received interferon plus ribavirin therapy 11 10 (90.9) 1 (9.1)
Unknown about treatment 53 42 (79.2) 11 (20.8)
Table 3 Status of the patient Infectious Detection *
Genotype Cross tabulation
Infectious Detection Genotype Total
3a Untypable 2a Mixed 1a 3b
HCV positive (Surgical
Patients)
15 20 6 3 2 3 49
(26.48%)
HCV positive (Pregnant
women)
71 0 2 0 1 0 2 0
(10.8%)
HCV positive (Blood
Donors)
97 1 3 3 0 2 3
(12.4%)
Unknown 26 26 5 5 3 9 74
(40.0%)
HCV positive (Foreign
screeners)
67 1 3 1 1 1 9
(10.3%)
Total 63 70 15 14 10 13 185
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viruses already present, allowing the new/resistant virus
to become the leading strain, therefore, in order to cor-
rectly genotype these newly emerged strains, clinical
laboratories may require to up date their genotyping
assays as the previously developed assays may not be
able to designate a specific genotype/subtype to these
strains.
Conclusion
We conclude that (i) HCV genotypes 3a is the most pre-
valent genotype in district Swat (ii) The current geno-
typing methods fail to genotype the newly emerged
strains (iii) Major mode of HCV transmission is
unknown.
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